Our data presented in this and previous studies [17] collectively demonstrated the existence of RG4 in at least four host factors (Ace2, Axl, Furin, and Tmprss2) that are considered as potential therapeutic targets for COVID-19. This evidence concerns the gene AXL and COVID-19.